Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx.
We describe 5 patients with severe pompholyx who did not respond to conventional therapy or who had debilitating side effects from corticosteroids. Low-dose methotrexate was added to their treatment regimens and led to significant improvement or clearing with a favorable side-effect profile. In all 5 patients the need for oral corticosteroid therapy was substantially decreased or eliminated, thus decreasing potential corticosteroid-induced morbidity. In this uncontrolled series of patients with recalcitrant palmoplantar pompholyx, methotrexate was an effective treatment and acted as a steroid-sparing agent.
Egan
C A
CA
Department of Dermatology, University of Utah School of Medicine, Salt Lake City 84132, USA.
Rallis
T M
TM
Meadows
K P
KP
Krueger
G G
GG
D000284:Administration, Oral; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D011146:Eczema, Dyshidrotic / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D013256:Steroids
D000893:Anti-Inflammatory Agents; D013256:Steroids; D008727:Methotrexate